Paclitaxel and topotecan in combination with rituximab as effective salvage regimen in relapsed or refractory aggressive non-Hodgkin's lymphoma.

被引：0
|
作者：
Canales, MA
Sanjurjo, MJ
Garcia-Vela, JA
de Paz, R
Gracia, J
Hernandez, D
Bustos, JG
Hernandez-Navarro, F
机构：
[1] Hosp Univ La Paz, Dept Hematol, Madrid, Spain
[2] Hosp Univ Getafe, Dept Hematol, Getafe, Spain
[3] Univ Autonoma Madrid, E-28049 Madrid, Spain
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4877
引用
收藏
页码：289B / 289B
页数：1
相关论文
共 50 条
  • [21] Results of GROC-rev salvage regimen: Gemcitabine, rituximab, and oxaliplatin chemotherapy with revlimid for relapsed/refractory aggressive non-Hodgkin lymphoma (NHL).
    Cabanillas, Fernando
    Liboy, Idalia
    Cruz, Alexis
    Solivan, Pedro Gil
    Rivera, Noridza
    Pardo, Wandaly Ibis
    Acosta, Mirelis
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Dexamethasone, high-dose cytarabine, and cisplatin (DHAP) in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma
    Mey, U
    Orlopp, K
    Flieger, D
    Strehl, J
    Ho, A
    Hensel, M
    Birkmann, J
    Wilhelm, M
    Kaiser, U
    Neubauer, A
    Glasmacher, A
    Schmidt-Wolf, I
    ANNALS OF ONCOLOGY, 2005, 16 : 180 - 180
  • [23] Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective salvage regimen for relapsed and refractory Hodgkin and non-Hodgkin's lymphoma: Results of a pilot study
    Corazzelli, G.
    Capobianco, G.
    Marcacci, G.
    Frigeri, F.
    Arcamone, M.
    Becchimanzi, C.
    Pinto, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 235 - 235
  • [24] Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study
    Corazzelli, G.
    Russo, F.
    Capobianco, G.
    Marcacci, G.
    Della Cioppa, P.
    Pinto, A.
    ANNALS OF ONCOLOGY, 2006, 17 : 18 - 24
  • [25] Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: Results of a pilot study
    Corazzelli, G
    Russo, F
    Capobianco, G
    Marcacci, G
    Della Cioppa, P
    Pinto, A
    BLOOD, 2005, 106 (11) : 276A - 277A
  • [26] ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma
    Choi, CW
    Paek, CW
    Seo, JH
    Kim, BS
    Shin, SW
    Kim, YH
    Kim, JS
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2002, 17 (05) : 621 - 624
  • [27] Etoposide, mitoxantrone and prednisone, a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma
    Doorduijn, JK
    Spruit, PH
    Van der Holt, B
    Van't Veer, MB
    Budel, LM
    Löwenberg, B
    Sonneveld, P
    HAEMATOLOGICA, 2000, 85 (08) : 814 - 819
  • [28] Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma
    Prichard, Mark
    Harris, Thomas
    Williams, Michael E.
    Densmore, John J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (06) : 983 - 995
  • [29] Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
    Wiernik, Peter H.
    Lossos, Izidore S.
    Tuscano, Joseph M.
    Justice, Glen
    Vose, Julie M.
    Cole, Craig E.
    Lam, Wendy
    McBride, Kyle
    Wride, Kenton
    Pietronigro, Dennis
    Takeshita, Kenichi
    Ervin-Haynes, Annette
    Zeldis, Jerome B.
    Habermann, Thomas M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (30) : 4952 - 4957
  • [30] Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin’s Lymphoma
    Gillian M. Keating
    Drugs, 2016, 76 : 1579 - 1586
12345